NEW YORK, July 12, 2016 /PRNewswire/ -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of North Carolina on behalf of investors who purchased TransEnterix, Inc. (NYSE MKT: TRXC) securities between February 10, 2016 and May 10, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/transenterix. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that (a) there were deficiencies within the Company's 510(k) application to the Food and Drug Administration which undermined the likelihood that the SurgiBot System would receive FDA clearance; (b) that as a result of these deficiencies, TransEnterix would be unable to commercialize the SurgiBot in 2016; and (c) consequently, the Company's ability to obtain approval for and commercialize its other robotic surgery platforms in the U.S. would be impaired.
If you suffered a loss in TransEnterix you have until August 1, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/transenterix.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq.
39 East Broadway
New York, NY 10002
E-Mail: [email protected]
SOURCE The Law Offices of Vincent Wong